Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after ...

Tivdak is the first and only ADC to be approved for people living with cervical cancer in Japan, noted Genmab, whose shares rose 3.2% to 1,399 kroner on the news. The drug was developed by Seagen, now ...

Tivdak, which Pfizer acquired through its acquisition of Seagen in December 2023, is the first ADC to have positive overall survival data for patients with previously treated recurrent or ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of multiple drug targets. The research and licence agreement will focus on advancing ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

Tivdak Market Report 2025 The Business Research Company's Global Tivdak Market Outlook 2025-2034: Growth Drivers, Share, And Trends It will grow to $XX million in ...

JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space. Published ...

Zai Lab has an exclusive license from Seagen Inc., acquired by Pfizer in 2023, to develop and commercialize TIVDAK in Greater China (mainland China, Hong Kong, Macau, and Taiwan, collectively).

Please see full U.S. prescribing information, including BOXED WARNING for TIVDAK here. Zai Lab has an exclusive license from Seagen Inc., acquired by Pfizer in 2023, to develop and commercialize ...